Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
Rhea-AI Summary
Harrow (Nasdaq:HROW) announced that management will present at William Blair’s 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.
The presentation will be webcast live on Harrow’s website, with a replay available for about 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – HROW
In the May 27 session, HROW gained 0.76%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Q1 2026 earnings | Negative | -23.7% | Q1 revenue with VEVYE adjustment and net loss prompted a sharp selloff. |
| Apr 27 | Earnings date notice | Neutral | +4.3% | Announcement of Q1 2026 earnings release and webcast schedule. |
| Apr 16 | Reimbursement update | Positive | +4.8% | Permanent J-code for IOPIDINE enabling in-office reimbursement from July 1, 2026. |
| Apr 14 | Distribution partnership | Positive | +2.2% | Selection of LogiCare3PL as U.S. distribution partner for ophthalmic products. |
| Mar 24 | Debt offering | Neutral | +3.3% | $50.0M senior unsecured notes due 2030 to support corporate initiatives. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent HROW news has generally seen price moves in the same direction as the underlying news tone, including a sharp selloff on Q1 results despite reiterated guidance.
Over the past several months, HROW has reported multiple operational and financial milestones. Q1 2026 results on May 11 showed strong product metrics but a net loss and triggered a -23.69% move. Earlier, the company announced a J-code for IOPIDINE on Apr 16 and a new distribution partner on Apr 14, both followed by gains. A $50.0 million senior notes offering on Mar 24 also coincided with a positive reaction. Today’s conference appearance fits into this ongoing investor outreach and commercialization story.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair’s 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.
The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.
Contact:
Mike Biega, Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890
